Key applications include: Growth hormone axis pharmacology characterizing the pharmacokinetics and pharmacodynamics of multi-peptide GHRH plus GHS-R1a co-stimulation and quantifying synergistic amplification of GH pulse amplitude IGF-1 axis research investigating the downstream effects of sustained and pulsatile GH elevation on hepatic IGF-1 production, tissue-level IGF-1 receptor activation, and anabolic signaling cascades in muscle, bone, and adipose tissue Body composition and metabolic research studying how GH secretagogue-induced GH elevation influences lipolysis, fat oxidation, lean mass preservation, and insulin sensitivity in research models Sleep architecture and GH secretion research examining the relationship between GH secretagogue-stimulated GH pulses and the deep sleep-associated GH release that is central to tissue repair and metabolic regulation Anti-aging and somatopause research investigating the role of GH axis decline in biological aging and whether secretagogue-mediated GH restoration can reverse or attenuate age-related changes in body composition, bone density, and metabolic function Muscle repair and recovery biology studying the mechanisms through which GH and IGF-1 elevation accelerates satellite cell activation, myofibrillar protein synthesis, and connective tissue repair following exercise or injury Ghrelin axis interaction studies using the differential selectivity profiles of Ipamorelin and GHRP-2 to dissect the contributions of pituitary versus hypothalamic GHS-R1a activation to the overall GH secretory response Dose-response and protocol optimization research characterizing how varying the timing, frequency, and relative component ratios of the triple blend influences GH pulse architecture, IGF-1 elevation magnitude, and downstream biological effects Key Research Outcomes Associated With GH Secretagogue Blend Protocols Published and ongoing research using CJC1295, Ipamorelin, GHRP-2, and their combinations has documented a range of biological outcomes that define the scientific value of this triple-peptide blend for investigators working across multiple research domains
Using the methionine-loading test, a postload homocysteine level above 38 mol/L and a postload increment above 27 mol/L increases the cardiovascular risk (Graham et al, 1997)
By activating its ubiquitously expressed receptor GLP1R, GLP-1 regulates multiple physiological processes which are summarized in Fig
We typically recommend IGF-1 testing at 3 months, 6 months, and then annually once stable
Most members start seeing meaningful progress within 2-3 monthsbut your bodys timeline is your own, and progress goes beyond a number on the scale
